TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06087822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMD SiPore21®
Description: The intended use/purpose to improve blood glucose control, as measured by a reduction in HbA1c

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IMD SiPore21®
Description: The intended use/purpose to improve blood glucose control, as measured by a reduction in HbA1c
Study: NCT06482515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Participants will be asked to eat all their food in a self-selected 10-hour eating window every day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: Participants will meet with a nutritionist to discuss their dietary habits and how they compare to the American Cancer Society nutrition guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition counseling
Description: Participants will meet with a nutritionist to discuss their dietary habits and how they compare to the American Cancer Society nutrition guidelines.
Study: NCT06268288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaCore intervention
Description: Use of the vagal nerve stimulator, GammaCore, on the right side of the neck for two 2 minute stimulations performed 3 times a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STEPS management protocol
Description: STEPS is the acronym for the standard management program for our patients with POTS. It includes liberal use of salt, taking in 90-100 ounces of fluid, gradually increasing the duration of aerobic exercise, possible use of one of two prescription medications (metoprolol, and midodrine), and encouragement to set priority and goals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STEPS management protocol
Description: STEPS is the acronym for the standard management program for our patients with POTS. It includes liberal use of salt, taking in 90-100 ounces of fluid, gradually increasing the duration of aerobic exercise, possible use of one of two prescription medications (metoprolol, and midodrine), and encouragement to set priority and goals
Study: NCT05959551

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: high definition transcranial direct current stimulation (HD-tDCS)
Description: HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation (HD-tDCS)
Description: HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation (HD-tDCS)
Description: HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation (HD-tDCS)
Description: HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation (HD-tDCS)
Description: HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.
Study: NCT06165471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online and offline blended teaching
Description: The Chaoxing app is an interventional tool, a professional mobile learning platform for smartphones, tablet computers, and other mobile terminals. They will learn the online course on the Chaoxing app and carry out offline classroom learning. The online courses focus on teaching design to make teaching PowerPoint, teaching videos, micro-lessons, homework library, and so on.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional teaching
Description: The researchers will implement the traditional teaching intervention of a surgical nursing practice course to the control group, and the teacher will demonstrate the operation procedure to the students face to face offline, and the students will practice. The whole intervention time is two months.
Study: NCT05307302

Intervention type: DIAGNOSTIC_TEST
Intervention: Force Sense
Description: A measure of proprioception, using a handheld dynamometer (MicroFET2-hoggan Health Industries Inc.), in a sitting position in a standardized position of the elbow joint of the dominant upper extremity (90 degree of flexion). Measurement of the elbow joint flexion force sense will be expressed as percentages. Each of the targeted trials will be calculated as a percentage of the maximum voluntary contraction (MVC) reference measure. The difference between the targeted and the actual percentage of MVC for each of the trials will be then calculated as a percentage of the targeted MVC, to reflect the proportion of error.
Study: NCT06171633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-STOP online educational program (treatment condition)
Description: Participants access online video modules through an online learning platform. Program includes modules on civility and upstander interventions and education about sexual harassment, microaggressions, and implicit bias.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-STOP online educational program (treatment condition)
Description: Participants access online video modules through an online learning platform. Program includes modules on civility and upstander interventions and education about sexual harassment, microaggressions, and implicit bias.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-STOP online educational program (control condition)
Description: Participants access online video modules through an online learning platform. Program includes authorship ethics only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-STOP online educational program (control condition)
Description: Participants access online video modules through an online learning platform. Program includes authorship ethics only.
Study: NCT05319353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants will receive maribavir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants will receive maribavir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants will receive maribavir.
Study: NCT06268964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimebutine
Description: Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimebutine
Description: Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus rhamnosus
Description: Prescription of Lactobacillus rhamnosus 5 billion CFUs in chewable tablets, a single dose (night) for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Description: Prescription of Lactobacillus rhamnosus 5 billion CFUs in chewable tablets, a single dose (night) for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Prescription of a placebo, 250 mg microcrystalline cellulose tablets, a single dose (night) for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Prescription of a placebo, 250 mg microcrystalline cellulose tablets, a single dose (night) for 8 weeks.
Study: NCT06027099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Tizanidine 2mg three times a day for 5 weeks after surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-Opioid Taper
Description: Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-Opioid Taper
Description: Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 tablet three times a day for 5 weeks after surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide \& Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.
Study: NCT05787925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid and Vitamin E
Description: 26 patients who will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase \* three times daily for 8 weeks applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application. In addition to one capsule of 400 mg oral systemic vitamin E supplement\* will be prescribed once daily at the morning
Study: NCT05905354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NWRD08
Description: Subjects in dose group 1 and 2 were intramuscularly injected with NWRD08 at week 0, week 4 and week 12 by electric pulse gene delivery instrument, respectively. Subjects in dose group 3 and 4 were intramuscularly injected NWRD08 at week 0, week 2, week 4 and week 12 by electric pulse gene delivery instrument, respectively.
Study: NCT06658041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)-based intervention with stepped-care
Description: After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]).~Mild symptoms (PHQ-9\<5) without major risks (\*see above): 4 weekly CBT-informed intervention sessions led by trained Emotional Support Assistants (Peer Supporters with 80hrs mental health training + 15hrs intensive clinical training).~Mild symptoms (PHQ-9\<5) with major risk factors or moderate-to-moderately severe symptoms (PHQ-9=10-19): 6 weekly CBT-based intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Individual CBT-based intervention will be provided to those unsuitable for group interventions.~In cases of non-remission (PHQ-9≥5): a second intervention trial will be provided. Those needing additional support will be referred to a partnered General Practitioner (if PHQ-9=10-19) or referred to more intensive psychological or psychiatric services as needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care-as-usual
Description: Following an initial interview session with research assessments, participants continue with their usual care at their primary care setting.
Study: NCT05307302

Intervention type: DIAGNOSTIC_TEST
Intervention: Joint Reproduction Sense
Description: A measure of proprioception, using a smart phone goniometer (Android Clinometer) application, in a sitting position in a standardized position of the elbow joint of the dominant upper extremity. Measurement of the elbow joint position reproduction will be expressed as degrees of reproduced angle. Absolute Error (AE) score will be calculated by the absolute value of the difference in degrees of the angle reproduced after subtracting the angle targeted.
Study: NCT04854356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with blood flow restriction (BFR)
Description: All participants completed high-intensity interval exercise plus (1) BFR applied during exercise phase, or (2) BFR applied during interval phase, or (3) no BFR applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise with blood flow restriction (BFR)
Description: All participants completed high-intensity interval exercise plus (1) BFR applied during exercise phase, or (2) BFR applied during interval phase, or (3) no BFR applied.
Study: NCT05307302

Intervention type: DIAGNOSTIC_TEST
Intervention: Seated Medicine Ball Throw
Description: A measure of upper limb physical performance, using 2-kg medicine ball and a standardized protocol, throwing distance expressed in meters.

Intervention type: DIAGNOSTIC_TEST
Intervention: Closed Kinetic Chain Upper Extremity Stability Test
Description: A measure of upper limb physical performance, using body weight and a standardized protocol, touches between hands expressed in number of touches.

Intervention type: DIAGNOSTIC_TEST
Intervention: Passing Accuracy
Description: A measure of the basketball passing skills, passing of The American Alliance for Health, Physical Education, Recreation and Dance (AAHPERD) test battery will be used in a standardized protocol. Accurate passes will be expressed in points.
Study: NCT05787925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroid
Description: 26 patients will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase three times daily for 8 week that will be applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application
Study: NCT05244083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Therapy consisting of perfoming bimanual activities with a mirror placed on the patient's sagital plane, so it creates the brain illusion that the impaired limb moves the same way and quality that the unimpaired does.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Program without Mirror Therapy
Description: Bimanual exercises performed with both upper limbs.
Study: NCT06454578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab + Apatinib
Description: the first 6 months or 8 cycles: Adebrelimab 1200 mg, every 3 weeks； Apatinib 250 mg/day~Maintenance phase： Adebrelimab 1200 mg, every 3 weeks, Maximum maintenance up to 2 years
Study: NCT05658133

Intervention type: OTHER
Group type: OTHER
Intervention: Survey of sports nutrition knowledge
Description: Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Survey of sports nutrition knowledge
Description: Questionnaire
Study: NCT06015269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC cells
Description: At a single arm, 1x107cells dose
Study: NCT05707702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic oral lozenges
Description: Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care for oral dysplasia
Description: Oral dysplasia standard of care includes clinical surveillance and risk factor reduction (such as smoking cessation).
Study: NCT06384872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoe Cushioning Position and Properties
Description: The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively, while remaining within the range of values of shoes available on the market (linear equivalent stiffness: about 40 to 60 and 50 to 80 N/mm, at the rear and forepart of the shoe, respectively). We expect a difference in shoe weight lower than 30 g between the three versions (for size 42). The difference in cushioning properties between shoe versions will be created by modifying the type of foam and the foaming process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoe Cushioning Position and Properties
Description: The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively, while remaining within the range of values of shoes available on the market (linear equivalent stiffness: about 40 to 60 and 50 to 80 N/mm, at the rear and forepart of the shoe, respectively). We expect a difference in shoe weight lower than 30 g between the three versions (for size 42). The difference in cushioning properties between shoe versions will be created by modifying the type of foam and the foaming process.
Study: NCT05386706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intervention
Description: This study developed a mini-program that combined diet, exercise, sleep, and mood interventions for PCOS women.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Traditional metformin monotherapy.
Study: NCT06165133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP)
Description: Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP) through an accredited training programme prior to commencing participation in the study
Study: NCT04844268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine
Description: Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT (HDT-301)) at a dose of 1 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
Study: NCT06384872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoe Cushioning Position and Properties
Description: The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively, while remaining within the range of values of shoes available on the market (linear equivalent stiffness: about 40 to 60 and 50 to 80 N/mm, at the rear and forepart of the shoe, respectively). We expect a difference in shoe weight lower than 30 g between the three versions (for size 42). The difference in cushioning properties between shoe versions will be created by modifying the type of foam and the foaming process.
Study: NCT04844268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine
Description: Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 5 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine
Description: Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 25 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.
Study: NCT06165133

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mesh inguinal hernia repair performed by fully trained surgeons
Description: Mesh inguinal hernia repair performed by fully trained surgeons, recognised by the Ghana College of Surgeons and Physicians and other recognised Surgical Colleges around the globe.
Study: NCT05310227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerivio
Description: The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache
Study: NCT05739019

Intervention type: OTHER
Intervention: frozen embryo transfer
Description: transfer one or two embryos in frozen embryo transfer cycles

Intervention type: OTHER
Intervention: frozen embryo transfer
Description: transfer one or two embryos in frozen embryo transfer cycles
Study: NCT04118998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abduction Loading
Description: The intervention for the experimental group entails practicing reaching with abduction loading.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supported Reaching
Description: The intervention for the active comparator entails practicing reaching while supported.
Study: NCT04844268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.
Study: NCT05512416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalpiciclib plus letrozole
Description: Six 4-week cycles of dalpiciclib orally, 150mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28
Study: NCT04871958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM, Dexcom G6)
Description: The Dexcom G6 sensor will be placed on the back of the upper arm at admission and changed after 10 days. In the participants randomized to Real-time CGM, glucose values will be transmitted through Bluetooth to a mobile phone at the bedside. From this phone data are transmitted to a tablet in the nursing station.~In the blinded CGM group, sensor readings will be blinded to patient and healthcare providers.~The MDI groups will be managed with basal/bolus insulin regimen, as clinically indicated.~V-Go will be placed on the abdomen each morning. Insulin-naïve patients randomized to the V-Go system will start at the lowest basal rate (20 UI/24h).~On daily basis, expert diabetologists will retrospectively review CGM data and provide indications for insulin therapy adjustments.
Study: NCT05011669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.